newswire, breaking biotechnology and pharma news

Wednesday, June 13, 2012

Medical Device Stock to Watch; Aethlon Medical (AEMD) Chairman and CEO Discusses Melanoma Exosomes

New York, New York - June 13, 2012 ( Newswire), an investor research portal specializing in sector research including biotech and pharma stocks, issues a news alert and company snapshot for Aethlon Medical (OTCBB:AEMD) , following news issued yesterday by the Company . Featuring commentary authored by Chairman and CEO, Jim Joyce on "Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis".
Aethlon Medical (OTCBB:AEMD) develops medical devices to address needs in cancer, infectious disease, and other life-threatening conditions.
"Our first research into cancer-secreted exosomes was driven by the curiosity that exosomes seemed to carry a unique high mannose signature that is found on the surface of glycoproteins that coat infectious viral pathogens. This signature happened to be the targeted binding site of the affinity agent immobilized in our Hemopurifier®, and provides the basis for our ability to selectively capture HCV, HIV, and a broad-spectrum of other viruses. In well-studied viruses such as HIV, we knew that surface glycoproteins can shed to trigger apoptosis or programmed cell death of immune cells. Therefore, it made sense to us that exosomes might have these same immunosuppressive properties. However, at the time we initiated our research, the medical community consensus was that exosomes were nothing more than cellular trash bags with no meaningful biologic function. In fact, there were only a handful of researchers with exosome focused research programs. This is no longer the case. Many cancer research institutes are now pursuing exosome driven initiatives as cancer-secreted exosomes have since been verified to play a significant role in the invasion of the immune system in cancer patients. Additionally, researchers now understand how exosomes contribute to the development of tumor angiogenesis as a mechanism for cancer to survive. The harmful role of exosomes is also being identified in other life threatening conditions, including sepsis, a disease we are studying under contract with the Defense Advanced Research Projects Agency (DARPA).
To date, we have demonstrated the ability to capture exosomes underlying a variety of cancers. As related to the discoveries by the Weill Cornell team, we fortuitously disclosed in September of 2010 that our Aethlon Hemopurifier® was able to capture exosomes derived from individuals with metastatic melanoma in a pre-clinical study. At present, we are fully focused on participating in a response to a new DARPA contract opportunity, expanding our HCV treatment studies, and preparing the resubmission of a investigational device exemption to FDA. Once these objectives have been advanced, we plan to discuss a potential melanoma treatment study that a U.S. based cancer research institute has proposed to conduct as a result of the Weill Cornell discoveries."
Full News:
About Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit
About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow on Twitter!/Investorideas
Follow on Facebook
Sign up for the free investor news and stock alerts at
Research biotech stocks at the Biotech stocks Directory
Become an Member
Follow on Twitter!/Investorideas
Follow on Facebook
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure is compensated by AEMD for news publication at and syndicated partners: four thousand eight hundred fifty for six months
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
Source -

No comments:

Post a Comment